Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 13/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014958 | 0.73 | PTGS2 (0.42) | PTGS2PTGS1GRIA1GRIA3PDE4D | |
| SCHEMBL6014856 | 0.70 | GRM5 (0.46) | PTGS2NTRK1GRIA1GRIA3PDE4D | |
| SCHEMBL6014879 | 0.70 | FABP3 (0.42) | PTGS2NTRK1GRIA1GRIA3PDE4D | |
| SCHEMBL28166222 | 0.69 | PTGS2 (0.41) | PTGS2PTGS1 | |
| SCHEMBL6014961 | 0.68 | GRIA1 (0.65) | GRIA1GRIA3PDE4D | |
| SCHEMBL6014924 | 0.66 | CYP2A6 (0.54) | NTRK1 | |
| SCHEMBL6014896 | 0.65 | CA12 (0.55) | PTGS2PTGS1 | |
| SCHEMBL6014906 | 0.64 | CYP2A6 (0.50) | GRIA1GRIA3PDE4D | |
| SCHEMBL6014865 | 0.63 | CYP2A6 (0.51) | — | |
| SCHEMBL13860632 | 0.61 | RAB9A (0.59) | PTGS1LMNAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189622-A1 | Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations | GRIK3, GRIK1, GRIK2 | PTGS2 2991/4885NTRK1 197/4885PTGS1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.